Published 1 day ago • loading... • Updated 1 day ago
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
Summary by The Manila Times
1 Articles
1 Articles
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right1Center0Last Updated100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium






